Research location
Bruay-la-Buissière
France
Advertisement
Research activity in Bruay-la-Buissière
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bruay-la-Buissière
9 linked trials · page 1 of 1A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaNCT02446418 · 2015-07-09 · 1 site observation
COMPLETED
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesNCT01289990 · 2011-02-01 · 1 site observation
COMPLETED
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 DiabetesNCT01159600 · 2010-07-01 · 1 site observation
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent AsthmaNCT01078688 · 2010-03-01 · 1 site observation
COMPLETED
National Survey on AsthmaNCT00770250 · 2008-09-01 · 1 site observation
COMPLETED
National Survey on Hypertension in Cardiologic Private PracticeNCT00695175 · 2008-02-01 · 1 site observation
COMPLETED
National Survey on Infiltrative Breast CancerNCT00696527 · 2007-06-01 · 1 site observation
COMPLETED
Cardiovascular Risk Assessment in Patients Treated With CaduetNCT00297973 · 2006-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.